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The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a
research program with the objective to impact on patient treatment by clinical disease stage characterization
(phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment
principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of
predictive and drug related protein biomarkers.
Data from joint lung cancer studies are presented where protein expression from Neuro- Endocrine lung cancer
(LCNEC) phenotype patients can be separated from Small cell- (SCLC) and Large Cell lung cancer (LCC) patients
by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized
by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre-therapeutic histological
distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An
establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy
by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative
(http://www.hupo.org) within chromosome 10 and chromosome 19 consortia.
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The Tokyo Medical University Hospital, a pioneer in
lung cancer treatment and surgery forms a center effort
jointly with Lund University Hospital to build an expert
capability resource. This joint establishment will inten-
sify the utility of cancer expertise and experiences in
both Japan and Sweden to benefit cancer patients. Clin-
ical samples will be sampled from the hospitals with
dedicated quality protocols and standard operating pro-
cedures (SOPs) by automated processing. These samples
will be archived in Biobank storages, and will be built as
a resource for R&D studies [1].* Correspondence: gyorgy.marko-varga@bme.lth.se
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in any medium, provided the original work is pToday we have a lack of protein biomarker-, and im-
aging diagnostics within most cancer disorders. New
clinical tools are expected to be used as early indicators
of disease, or, as personalized indicator assays for tar-
geted and stratified disease phenotype drug treatments
in the near future. There is also a poor understanding of
the mode of drug action mechanisms, by commonly
used therapies, which is also true for new drugs intro-
duced to the market. The actual targeted cells-, and pro-
teins within disease, and the actual drug interactions are
by no means understood for most medicines used in
today’s therapies. These drug characteristics are needed
for both efficacy-, and safety improvements, and also
requested by regulatory authorities like; FDA/EMA/
MHLW.
New technology developments that can be used to tar-
get the specificity and efficacy of new drug treatments
within the health care system is progressing withis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Europe. The new generation of drugs with mono-specific
affinity will require more in depth knowledge in order to
provide a tailor made cure to all patients taking the drug.
The aim and purpose of the Swedish-Japanese research
program is to develop new insights into disease presen-
tation and the disease progression. These objectives are
intimately linked to the classification of patients that
presents similar pathologies in disease. The stratification
of these patients is an added value to both the healthcare
sector as well as the drug industry, as it will point to the
ability to optimize the treatment of cancer patients. A
cornerstone of the Japanese-Swedish hospital initiatives
will be to develop new Multiple Reaction Monitoring
(MRM) Multiplex analysis methods for cancer, that
can be used in combination with CT-imaging and patho-
physiology diagnosis. At present, there is a lack of
disease specific radiographic markers or protein/peptide
biomarkers. These new biomarkers should be introduced
into routine clinical practice to support clinical decision
making for the management of common diseases that
are consequent to life styles, but also to genetic heritage.
The developed methods and technologies outlined here
will bring new opportunities for describing the indices of
pathogenesis that are associated with the processes of
early disease development. Our research teams have
previously been successful in presenting lung cancer bio-
marker candidates [2-4]. We propose to continue devel-
oping new Protein Biomarker Diagnosis Panels that can
measure novel patterns of structural and functional
marker expression that precede and predict certain dis-
ease development. The biology change within disease
will be followed by alterations due to drug intervention.
Drug compound localization in pulmonary tissue will be
characterized in lung cancer and COPD tissue by im-
aging mass spectrometry. The aim is to further probe
the drug and metabolite(s) content and distribution in
tissues. Following administration and drug exposure,
drug parent ion (m/z) and fragmented daughter ions will
be analyzed by spatially localization, after scanning the
histology section in the MALDI instrument at single cell
level [5,6]. The joint teams will also focus on excellence
in biological and medical mass spectrometry, that pro-
vides health care institutions with expertise in clinical
proteomics, drug imaging and mass spectrometry aiming
at developing new diagnostic tools that can be integrated
in routine clinical medicine. We have a major challenge
in modern healthcare in both Japan and Sweden, to pro-
vide the right medicine to the right patient at the right
time. Targeted treatment defined as “Personalized medi-
cine” is becoming the next generation of drugs where
drug efficacy and patient safety, is expected to predict
the stratified treatment. In these developments, it is ex-
pected that patients will benefit by effective curing, andsociety will benefit by financial resources with increased
efficiencies at a lower cost.
Global healthcare and drug developments
There is a highly unmet need within the healthcare sec-
tor that calls for an increasing world-wide demand for
new medicines and curative therapies to aid in the treat-
ment of cancer patients.
We need to utilize and apply cutting edge research
with state-of-art facilities more efficiently and drive op-
portunities that can be used in order to impact on pro-
viding quality care that extend prognosis.
In this respect, the pharmaceutical industry and its
drug product provider responsibility is under major re-
structuring. The main objective for pharmaceutical in-
dustry is to provide more specific and more efficacious
drugs by targeted treatment, i.e. by Personalized Medi-
cine (PM), and to provide the diagnostic test that will
direct the right patient group to the right drug. We out-
lined the directives of these principles recently in a white
paper [7], predicting a future link in-between PM and
diagnostic guidance. Today, this is an accepted concept
and is being applied in Japan as the first country;
The Clinical Practice Guideline, (from The Japan Lung
Cancer Society (https://www.haigan.gr.jp/modules/guideline/
index.php?content_id=3)).
In practice this means and results in that the Biomarker
diagnostic research is increasing. Companion diagnostics
is an area of impressive growth, where the pharmaceutical
industry, the biotech sector, and academia are investing
considerable resources.
The national healthcare expenses are also increasing for
most countries in the western world, where the US
is in the lead, spending >17% national healthcare expenses/
GDP (Shown in Figure 1). The growth is almost 5% over
the last two decades. Japan reaches almost 10% which is
very similar levels of healthcare budgets as Sweden. The
Japanese healthcare expense was 38.6 trillion yen in 2011
and 40 trillion yen in 2013. This cost continues to increase
by 1 trillion yen/year, looking at the recent three years.
Interestingly, China and Russia are on the lower end of
healthcare spending with 5% and 6%, respectively.
The expenses that each country needs to provide for
their respective healthcare is tightly associated with the
development of new medicines.
Currently, the global pharmaceutical industry is
worth $300 Bill, and is expected to be rising to $400
Bill by 2015. In addition, the market size for pharma-
ceuticals now exceeds $1 trillion and is continuously
growing. This industry is very profitable, and currently
employing about 1.5 million people within the US and
EU-countries.
In this regards, the R&D investments in within this
industry have consistently managed to grow with
Figure 1 Statistical presentation of national healthcare spending/GDP in countries in-between 1995-2012.
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having a total spend on R&D with more than $100
Bill, per annum.
As the Research and Development phases of drug de-
velopment is a long-term investment for the pharma in-
dustry, taking into account that most drugs fail long
before getting to market, there is an incentive strive to
find new strategies and operating principles.
Cancer research
Cancer diseases are some of the most costly for our soci-
eties. Processes essential to growth and replication of
tumor cells and the maintenance of their supportive
microenvironment such as the angiogenesis are today
target strategies for cancer therapy.
Established chemotherapeutic agents and many novel
agents in developments are directed towards various as-
pects of these essential cellular processes.
Over the years, we have been involved in developments
associated with target proteins, possessing key regulatory
functions in cancer [3,8,9]. They are as follows;
 Growth factor signaling such as EGFR






 TGFBAs these growth factors stimulate cell growth by inter-
acting with internal domains of the trans-membrane re-
ceptors, we will sequence the variety of targeted proteins
in order to get a better understanding of the underlying
tumor mechanisms. Previous data has been guiding in
this respect [10,11].
Other oncological processes that will be directed within
the joint cancer studies incorporate;
a) metastasis
b) angiogenesis that includes VEGF
c) DNA replication, including transcription and repair
d) histone acetylation and de-acetylation that can be
mapped by mass spectrometry
Upon growth factor receptor binding to targets such
as EGF, FGF, and TGFB, the activation of tumor biology
is initiated [3,5,6,8,12]. This ligand-receptor complex for-
mation also imposes conformational changes of the re-
ceptor which will result in an activation of the transfer
of phosphate groups. The autophosphorylation loop of
the kinase is the target area of mass spectrometry deep-
mining of these regions within the protein sequence
[13-15].
Establishing the identity of the amino acids that are
phosphorylated is of high interest.
By dedicated clinical study materials from various
patient groupings our objective is to map the receptor-
ligand interactions. The glycolytic post-translational-
modifications (PTM) of any given ligand activator will
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tus of the receptor itself has also proven to be of major
importance to the signaling mechanisms [16]. We re-
cently outlined a strategic overview of key protein tar-
gets, playing a key role in pancreatic cancer [16]. The
TGF-β receptor and TGF- β ligand has a direct role in
the development of lung cancer as well as other cancer
forms [15].
On a molecular level, the intracellular targets, with
specific assigned function in cancer are enzymes which
activities catalysis the signaling cascade through the cel-
lular regions reaching the nucleus. We have previously
been working with ERK and MAPKAP signaling, as well
as ZAP70. ZAP70 is a key target in a number of cancer
types and is responsible for the autophosphorylation, of
specific threonine positions within the protein that can be
determined [13,14]. The stoichiometric distribution of
phosphor-groups being post-translationally modified has
been pioneered by our research team. Sequencing of the
target peptide of this tyrosine kinase can be accomplished
by both ESI- as well as MALDI- mass spectrometry.
We recently reported on the development of bio-
markers on the newly identified neuroendocrine pheno-




Figure 2 Deep sequencing of proteins in LCNEC patient samples in coWe have followed up with new protein sequencing ex-
periments where the expression specificity of the LCNEC
phenotype can be identified, as shown in Figure 2. A clear
differential expression pattern can be seen in comparison
to LCC and SMC. The difference in expression constitutes
proteins with both medium-, as well as low-abundant ex-
pression (unpublished data).
Interestingly, these LCNEC Carcinoid tumors originate
from cells that belong to the diffuse neuroendocrine sys-
tem. These cells resembles nerve cells in certain ways,
but they are also alike hormone-making endocrine cells
in other ways. This phenotype of tumor cells are local-
ized throughout the body, found in organs like the lungs,
intestines, as well as the stomach [2].Protein deep sequencing platform and biobanking
Mining the data output from protein deep sequencing
studies is an intense research activity where the chromo-
some initiative has presented impressive novel annotation
deliveries [17-21]. The HUPO database; NextProt provides
evidence detail on status output of chromosome 10 and 19
(http://www.nextprot.org).
Currently the remaining unknown proteins, coded by
the human genome are 27% [17].EC SCLC
mparison to LCC and SCLC.
A)  Sequence DB Search
B)  Spectral library Search
C)  Sequence-tag/hybrid Search
Spectral library
Human Prot. DB
D)  De novo sequencing  
Ranked peptide list















Figure 3 Workflow with LC-MS platform integrated to search engines for the annotation of proteins.
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Exchange database and include post-translational modi-
fications as well as splice variants and protein isomers
[22]. Details of the experimental outputs were published
in a special issue in 2014, presenting the major develop-
ments from the C-HPP chromosome teams [18,19,21,23].
22 global chromosome team published papers on the
novel annotations, including database reports with neXt-
Prot, PeptideAtlas, and CAPER.
A recent development was made jointly by the TMU-
LUH research teams, assigning a specific protein deep
sequencing platform and work-flow. We are currently
applying the process in lung cancer studies where we
target novel proteoforms of missing gene coded proteins.
The workflow process as we currently use in laboratories
in both Tokyo and Lund is depicted in Figure 3.Figure 4 Exploring new governance paradigms for Biobanks.Large scale Biobanking is presently an intense clinical
activity in hospitals around the world. Recently, Bio-
banking was recognised by the TIME Magazine as One
of; “10 Ideas Changing the World Right Now”. We will
continue to establish biobank capabilitiesis, a first step
towards realizing the vision of a comprehensive access
to TMU-LUH biobank samples. We will combine these
samples with health register data, thereby identifying
correlations in-between clinical variables and disease
presentations in patients. Currently we are using a re-
source driven sample collection, as outlined in Figure 4.
We are coordinating sample collections in-between
TMU and LUH, utilizing robotic -80 °C sample handling
systems as previously described [1,24-27]. The ultra-low
temperature storage is essential as it ensures the stability
of proteins within the clinical samples. Blood samples
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quoted in 384-sample tube systems, developed by our
research team [25]. The 384 high-density rack system
will provide a cost-benefit advantage, and expected to
become a new standard in modern biobanking. This allows
HUPO to easily process Biobank samples globally.
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